Bleomycin
Bleomycin (bleomycin) is a small molecule pharmaceutical. Bleomycin was first approved as Blenoxane on 1982-01-01. It is used to treat choriocarcinoma, hodgkin disease, melanoma, non-hodgkin lymphoma, and sarcoma amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Bleomycin (discontinued: Blenoxane, Bleomycin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bleomycin sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BLENOXANE | Bristol Myers Squibb | N-050443 DISCN | 1982-01-01 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bleomycin | ANDA | 2024-10-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| non-hodgkin lymphoma | — | D008228 | C85.9 |
| sarcoma | — | D012509 | — |
| hodgkin disease | — | D006689 | C81 |
| melanoma | — | D008545 | — |
| squamous cell carcinoma | — | D002294 | — |
| testicular neoplasms | — | D013736 | C62 |
| choriocarcinoma | — | D002822 | C58 |
| teratocarcinoma | — | D018243 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9040 | Injection, bleomycin sulfate, 15 units |
Clinical
Clinical Trials
210 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | — | — | — | 1 | — | 1 |
| Hiv | D006678 | — | O98.7 | — | — | — | 1 | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | 1 | — | 1 |
| Kaposi sarcoma | D012514 | — | C46 | — | — | — | 1 | — | 1 |
| Human herpesvirus 8 | D019288 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bleomycin |
| INN | bleomycin |
| Description | Bleomycin A2 is a bleomycin. It has a role as an antineoplastic agent and a metabolite. |
| Classification | Small molecule |
| Drug class | antibiotics (Streptomyces strain) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1 |
Identifiers
| PDB | — |
| CAS-ID | 11056-06-7 |
| RxCUI | 1622 |
| ChEMBL ID | CHEMBL403664 |
| ChEBI ID | 3139 |
| PubChem CID | 5460769 |
| DrugBank | DB00290 |
| UNII ID | 40S1VHN69B (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 51,977 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bleomycin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9,996 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use